Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata

Astellas’ FLT3 inhibitor for acute myeloid leukaemia (AML) – Xospata – has been recommended for approval in Europe, giving it a further lead over a rival drug from Daiichi Sankyo.